Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSCF Pharma
About this trial
The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.
Eligibility criteria
Qualifiers
Participant aged of at least 18 years old.
Disqualifiers
Participant who use omega-3 supplements and / or anti-inflammatory medication such as, but not limited to - Aspirin, Ibuprofen (Motrin, Advil), Celecoxib (Celebrex), diclofenac (Cambia, Cataflam, Voltaren ) within 7 days of day 1 of the study.
Trial design
Treatments tested in this trial
- MAG-SPM treatment on isolated PBMC cells
- Isolated PBMC cells without treatment.
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov